Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation.

Ghassemieh B, Ahya VN, Baz MA, Valentine VG, Arcasoy SM, Love RB, Seethamraju H, Alex CG, Bag R, DeOliveira NC, Vigneswaran WT, Charbeneau J, Garrity ER, Bhorade SM.

J Heart Lung Transplant. 2013 Jul;32(7):701-6. doi: 10.1016/j.healun.2013.04.010. Epub 2013 May 7.

PMID:
23664526
2.

Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.

Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB, Wang SS, Dong G, Witte S, Junge G, Potena L.

Transpl Infect Dis. 2013 Apr;15(2):150-62. doi: 10.1111/tid.12007. Epub 2012 Sep 26.

PMID:
23013440
3.

Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials.

Demopoulos L, Polinsky M, Steele G, Mines D, Blum M, Caulfield M, Adamkovic A, Liu Q, Harler MB, Hahn C, Singh A.

Transplant Proc. 2008 Jun;40(5):1407-10. doi: 10.1016/j.transproceed.2008.03.084.

PMID:
18589118
4.

The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation.

Sheng L, Jun S, Jianfeng L, Lianghui G.

Clin Transplant. 2015 Jun;29(6):555-9. doi: 10.1111/ctr.12552. Epub 2015 May 6.

PMID:
25851741
5.

The incidence of cytomegalovirus infection in lung transplant recipients under universal prophylaxis with intravenous ganciclovir.

Schröeder R, Michelon T, Wurdig J, Fagundes I, Schio S, Sanchez L, Camargo JJ, Sukkienik TC, Pasqualotto AC, Neumann J.

Braz J Infect Dis. 2007 Apr;11(2):212-4.

6.

Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.

Rittà M, Costa C, Solidoro P, Sidoti F, Libertucci D, Boffini M, Rinaldi M, Baldi S, Cavallo R.

Antiviral Res. 2015 Jan;113:19-26. doi: 10.1016/j.antiviral.2014.10.016. Epub 2014 Nov 7.

7.

A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.

Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizón JM, Simonsen S, Abeywickrama KH, Bara C.

Transplantation. 2007 Dec 15;84(11):1436-42.

PMID:
18091519
8.

Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation.

Bhorade S, Ahya VN, Baz MA, Valentine VG, Arcasoy SM, Love RB, Seethamraju H, Alex CG, Bag R, Deoliveira NC, Husain A, Vigneswaran WT, Charbeneau J, Krishnan JA, Durazo-Arvizu R, Norwick L, Garrity E.

Am J Respir Crit Care Med. 2011 Feb 1;183(3):379-87. doi: 10.1164/rccm.201005-0775OC. Epub 2010 Sep 10.

PMID:
20833822
9.

Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.

Nashan B, Gaston R, Emery V, Säemann MD, Mueller NJ, Couzi L, Dantal J, Shihab F, Mulgaonkar S, Seun Kim Y, Brennan DC.

Transplantation. 2012 Jun 15;93(11):1075-85. doi: 10.1097/TP.0b013e31824810e6. Review.

PMID:
22683823
10.

Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.

Haririan A, Morawski K, West MS, El-Amm JM, Doshi MD, Cincotta E, Alangaden GJ, Chandrasekar P, Gruber SA.

Clin Transplant. 2007 Jul-Aug;21(4):466-71.

PMID:
17645705
11.

Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients.

Ozaki KS, Câmara NO, Galante NZ, Camargo LF, Pacheco-Silva A.

Int Immunopharmacol. 2005 Jan;5(1):103-6.

PMID:
15589467
12.

Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.

Kruger RM, Paranjothi S, Storch GA, Lynch JP, Trulock EP.

J Heart Lung Transplant. 2003 Jul;22(7):754-63.

PMID:
12873543
13.
14.

Incidence and predictive factors for cytomegalovirus infection in renal transplant recipients.

Corona-Nakamura AL, Monteón-Ramos FJ, Troyo-Sanromán R, Arias-Merino MJ, Anaya-Prado R.

Transplant Proc. 2009 Jul-Aug;41(6):2412-5. doi: 10.1016/j.transproceed.2009.05.008.

PMID:
19715936
15.

CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.

Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A.

Clin Transplant. 2008 Jan-Feb;22(1):89-97. doi: 10.1111/j.1399-0012.2007.00750.x.

PMID:
18217909
16.

Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.

Andrassy J, Hoffmann VS, Rentsch M, Stangl M, Habicht A, Meiser B, Fischereder M, Jauch KW, Guba M.

Transplantation. 2012 Dec 27;94(12):1208-17. doi: 10.1097/TP.0b013e3182708e56. Review.

PMID:
23269449
17.

Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients.

Bhorade SM, Lurain NS, Jordan A, Leischner J, Villanueva J, Durazo R, Creech S, Vigneswaran WT, Garrity ER.

J Heart Lung Transplant. 2002 Dec;21(12):1274-82.

PMID:
12490272
18.

Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.

Palmer SM, Grinnan DC, Diane Reams B, Steele MP, Messier RH, Duane Davis R.

Clin Transplant. 2004 Apr;18(2):179-85.

PMID:
15016133
20.

Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group.

Falagas ME, Snydman DR, George MJ, Werner B, Ruthazer R, Griffith J, Rohrer RH, Freeman R.

Transplantation. 1996 Jun 27;61(12):1716-20.

PMID:
8685949

Supplemental Content

Support Center